Baxdela Approval History
- FDA approved: Yes (First approved June 19th, 2017)
- Brand name: Baxdela
- Generic name: delafloxacin
- Dosage form: Tablets and Injection
- Company: Melinta Therapeutics
- Treatment for: Skin and Structure Infection
Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
Development History and FDA Approval Process for Baxdela
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.